CS1 in Phase II
Lead candidate CS1 is a well-tolerated oral therapy with a favorable safety profile and showed signals of disease-modifying effects as observed in a Phase IIa trial in patients with the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC inhibitor acting with epigenetic modulation. The aim for CS1 is to offer an effective disease-modifying treatment with the ability to enhance quality of life and extend life for PAH patients. Unlike standard therapy that focus on managing symptoms, CS1 represents a novel therapeutic approach by targeting the root mechanisms of PAH. Specifically, CS1 aims to reverse the pathological vascular remodeling of the small pulmonary arteries.
CS014 in Phase I
CS014 is a proprietary new chemical entity, a deuterated VPA, with a multimodal mechanism of action. Being an epigenetic modulator, CS014 has the potential to target the underlying pathophysiology of several rare cardiovascular and pulmonary diseases with high unmet medical needs. The initial target is idiopathic pulmonary fibrosis (IPF). In preclinical studies, CS014 has demonstrated strong effects on vascular remodeling, suggesting disease-modifying potential.
CS585 in preclinical phase
CS585 is an oral, highly potent, and selective prostacyclin (IP) receptor agonist developed to address key disease mechanisms in cardiovascular conditions. Preclinical studies suggest that CS585 has the potential to offer effective thrombosis prevention without increasing bleeding risk, a major limitation of current anti-thrombotic therapies. Additionally, CS585 shows promise in the treatment of pulmonary hypertension and other rare diseases with significant unmet needs. The target indication for CS585 is currently under evaluation based on these promising preclinical findings.